CINV – Can We Make It a Thing of the Past? - priME Oncology

CINV – Can We Make It a Thing of the Past?

Not a member of My prIME? Join now for instant access.

This activity features interactive flashcards covering key topics from Chemotherapy-Induced Nausea and Vomiting – Can We Make It a Thing of the Past?, a prIME Oncology symposium held in Denver, Colorado, United States.



0.4 Contact Hour

Release Date

Release Date

Jun 16, 2017

Expiration Date

Jun 16, 2018

The proposed educational activity is specifically designed to meet the needs of oncology nurses and other healthcare professionals involved in the treatment of patients with chemotherapy-induced nausea and vomiting (CINV).

After successful completion of this educational activity, participants should be able to:

  • Describe the physiologic principles underlying CINV and radiotherapy-induced nausea and vomiting
  • Identify current guideline-based treatments and the unmet medical need for further improvements in CINV management
  • Evaluate the most current clinical data on prevention and treatment of CINV, with an emphasis on long-acting neurokinin 1 (NK-1) receptor antagonists

This educational activity is supported by grants from Helsinn Oncology and TESARO, Inc.

Continuing Education

This continuing nursing education activity was approved by the ONS, an accredited approver by the American Nurses Credentialing Center’s COA.

A maximum of 0.4 contact hour may be earned for successful completion of this program.

Content in this learning activity is applicable to meeting individual requirements for certification renewal through the Oncology Nursing Certification Corporation’s Independent Learning Needs Assessment (ILNA) renewal method. Visit for complete details on oncology nursing certification.


This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

The employees of prIME Oncology have disclosed:

  • Robert Coleman, MBBS MD FRCP, FRCPE (medical director content reviewer/planner) – receipt of research funding from Amgen and Bayer
  • Zach Hartman, PhD (clinical content reviewer/planner) – stock or stock options in Advaxis, Inc. and Ariad Pharmaceuticals
  • Brooke Balun, NP (nurse planner) – no relevant financial relationships
  • Christi Gray (editorial content reviewer) – no relevant financial relationships


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.